Mark A. Goldsmith's most recent trade in Revolution Medicines Inc was a trade of 13,775 Common Stock done at an average price of $199.3 . Disclosure was reported to the exchange on Sept. 16, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 199.30 per share. | 16 Sep 2026 | 13,775 | 253,342 (0%) | 0% | 199.3 | 2,745,402 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 195.01 per share. | 16 Sep 2026 | 213 | 267,117 (0%) | 0% | 195.0 | 41,537 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 21 Aug 2026 | 80,000 | 347,330 (0%) | 0% | 4.7 | 378,400 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 Aug 2026 | 80,000 | 344,085 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 209.26 per share. | 21 Aug 2026 | 35,938 | 281,347 (0%) | 0% | 209.3 | 7,520,440 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 208.37 per share. | 21 Aug 2026 | 24,917 | 317,285 (0%) | 0% | 208.4 | 5,191,948 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 211.33 per share. | 21 Aug 2026 | 6,583 | 270,951 (0%) | 0% | 211.3 | 1,391,206 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 207.23 per share. | 21 Aug 2026 | 5,128 | 342,202 (0%) | 0% | 207.2 | 1,062,691 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 210.25 per share. | 21 Aug 2026 | 3,813 | 277,534 (0%) | 0% | 210.2 | 801,670 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 212.08 per share. | 21 Aug 2026 | 3,621 | 267,330 (0%) | 0% | 212.1 | 767,933 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 209.27 per share. | 21 Aug 2026 | 1,405 | 61,905 (0%) | 0% | 209.3 | 294,019 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 209.28 per share. | 21 Aug 2026 | 1,351 | 61,932 (0%) | 0% | 209.3 | 282,739 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 208.36 per share. | 21 Aug 2026 | 951 | 63,283 (0%) | 0% | 208.4 | 198,155 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 208.36 per share. | 21 Aug 2026 | 937 | 63,310 (0%) | 0% | 208.4 | 195,234 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 211.47 per share. | 21 Aug 2026 | 245 | 61,551 (0%) | 0% | 211.5 | 51,809 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 211.46 per share. | 21 Aug 2026 | 229 | 61,550 (0%) | 0% | 211.5 | 48,425 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 207.25 per share. | 21 Aug 2026 | 190 | 64,234 (0%) | 0% | 207.2 | 39,377 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 207.25 per share. | 21 Aug 2026 | 177 | 64,247 (0%) | 0% | 207.3 | 36,684 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 210.40 per share. | 21 Aug 2026 | 136 | 61,796 (0%) | 0% | 210.4 | 28,615 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 212.06 per share. | 21 Aug 2026 | 127 | 61,424 (0%) | 0% | 212.1 | 26,932 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 212.06 per share. | 21 Aug 2026 | 126 | 61,424 (0%) | 0% | 212.1 | 26,720 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 210.40 per share. | 21 Aug 2026 | 126 | 61,779 (0%) | 0% | 210.4 | 26,511 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 156.12 per share. | 16 Jun 2026 | 10,020 | 267,330 (0%) | 0% | 156.1 | 1,564,310 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 150.09 per share. | 15 Apr 2026 | 120,000 | 276,698 (0%) | 0% | 150.1 | 18,010,488 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2026 | 96,756 | 424,085 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.73 per share. | 15 Apr 2026 | 96,756 | 396,698 (0%) | 0% | 4.7 | 457,656 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Apr 2026 | 23,244 | 24,464 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 15 Apr 2026 | 23,244 | 299,942 (0%) | 0% | 4.1 | 95,068 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 99.48 per share. | 17 Mar 2026 | 12,871 | 276,698 (0%) | 0% | 99.5 | 1,280,412 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Feb 2026 | 24,010 | 144,493 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 06 Feb 2026 | 24,010 | 256,479 (0%) | 0% | 0.5 | 12,965 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 76.82 per share. | 16 Dec 2025 | 15,394 | 232,469 (0%) | 0% | 76.8 | 1,182,526 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 25 Nov 2025 | 60,000 | 307,863 (0%) | 0% | 4.1 | 245,400 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2025 | 60,000 | 77,708 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 75.08 per share. | 25 Nov 2025 | 60,000 | 247,863 (0%) | 0% | 75.1 | 4,504,962 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 25 Nov 2025 | 3,000 | 67,424 (0%) | 0% | 75 | 225,000 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 75.00 per share. | 25 Nov 2025 | 3,000 | 67,424 (0%) | 0% | 75 | 225,000 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 70.38 per share. | 18 Nov 2025 | 20,000 | 247,863 (0%) | 0% | 70.4 | 1,407,586 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Nov 2025 | 20,000 | 137,708 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 18 Nov 2025 | 20,000 | 267,863 (0%) | 0% | 4.1 | 81,800 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Nov 2025 | 20,000 | 157,708 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 65.07 per share. | 12 Nov 2025 | 20,000 | 247,863 (0%) | 0% | 65.1 | 1,301,410 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 12 Nov 2025 | 20,000 | 267,863 (0%) | 0% | 4.1 | 81,800 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Nov 2025 | 50,000 | 54,498 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Nov 2025 | 50,000 | 70,424 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Nov 2025 | 50,000 | 247,863 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Gift of securities by or to the insider at price $ 0.00 per share. | 07 Nov 2025 | 50,000 | 297,863 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 60.31 per share. | 07 Nov 2025 | 30,000 | 347,863 (0%) | 0% | 60.3 | 1,809,306 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 07 Nov 2025 | 26,479 | 374,342 (0%) | 0% | 1.1 | 29,656 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2025 | 26,479 | 0 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Nov 2025 | 3,521 | 177,708 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 07 Nov 2025 | 3,521 | 377,863 (0%) | 0% | 4.1 | 14,401 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.00 per share. | 16 Oct 2025 | 10,000 | 452,309 (0%) | 0% | 55 | 550,000 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 16 Oct 2025 | 10,000 | 462,309 (0%) | 0% | 1.1 | 11,200 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 50.47 per share. | 16 Oct 2025 | 10,000 | 452,309 (0%) | 0% | 50.5 | 504,701 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.12 per share. | 16 Oct 2025 | 10,000 | 462,309 (0%) | 0% | 1.1 | 11,200 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2025 | 10,000 | 26,479 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Oct 2025 | 10,000 | 36,479 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.82 per share. | 16 Sep 2025 | 13,411 | 452,309 (0%) | 0% | 45.8 | 614,558 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2025 | 37,000 | 168,503 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 30 Jun 2025 | 37,000 | 465,720 (0%) | 0% | 0.5 | 19,980 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.83 per share. | 16 Jun 2025 | 13,496 | 428,720 (0%) | 0% | 39.8 | 537,546 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.04 per share. | 17 Mar 2025 | 11,738 | 441,564 (0%) | 0% | 39.0 | 458,255 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 341,100 | 0 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2025 | 97,400 | 453,302 (0%) | 0% | 0 | Common Stock | |
| Revolution Medicines Inc | Goldsmith A. Mark | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Dec 2024 | 30,846 | 0 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.49 per share. | 18 Dec 2024 | 30,846 | 355,902 (0%) | 0% | 0.5 | 15,115 | Common Stock |
| Revolution Medicines Inc | Goldsmith A. Mark | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.40 per share. | 16 Dec 2024 | 11,714 | 325,056 (0%) | 0% | 45.4 | 531,860 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 50,900 | 181,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.56 per share. | 01 Nov 2024 | 50,900 | 300,170 (0%) | 0% | 55.6 | 2,827,821 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 01 Nov 2024 | 50,900 | 351,070 (0%) | 0% | 4.1 | 208,181 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 36,600 | 30,846 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.49 per share. | 01 Nov 2024 | 36,600 | 336,770 (0%) | 0% | 0.5 | 17,934 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 01 Nov 2024 | 9,100 | 309,270 (0%) | 0% | 4.1 | 37,219 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Nov 2024 | 9,100 | 232,129 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.02 per share. | 01 Nov 2024 | 9,100 | 300,170 (0%) | 0% | 55.0 | 500,714 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.02 per share. | 01 Nov 2024 | 5,000 | 20,424 (0%) | 0% | 55.0 | 275,105 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 55.03 per share. | 01 Nov 2024 | 5,000 | 20,424 (0%) | 0% | 55.0 | 275,134 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 11 Oct 2024 | 30,000 | 330,170 (0%) | 0% | 4.1 | 122,700 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 50.36 per share. | 11 Oct 2024 | 30,000 | 300,170 (0%) | 0% | 50.4 | 1,510,773 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 30,000 | 241,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 01 Oct 2024 | 10,000 | 310,170 (0%) | 0% | 4.1 | 40,900 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Oct 2024 | 10,000 | 271,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 44.80 per share. | 01 Oct 2024 | 7,978 | 302,192 (0%) | 0% | 44.8 | 357,409 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.46 per share. | 01 Oct 2024 | 2,022 | 300,170 (0%) | 0% | 45.5 | 91,913 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 44.19 per share. | 16 Sep 2024 | 11,715 | 300,170 (0%) | 0% | 44.2 | 517,631 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 01 Aug 2024 | 10,000 | 321,885 (0%) | 0% | 4.1 | 40,900 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Aug 2024 | 10,000 | 281,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.60 per share. | 01 Aug 2024 | 6,783 | 315,102 (0%) | 0% | 45.6 | 309,308 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 46.48 per share. | 01 Aug 2024 | 3,217 | 311,885 (0%) | 0% | 46.5 | 149,519 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Jul 2024 | 25,000 | 291,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.05 per share. | 12 Jul 2024 | 25,000 | 311,885 (0%) | 0% | 45.0 | 1,126,205 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 12 Jul 2024 | 25,000 | 336,885 (0%) | 0% | 4.1 | 102,250 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.01 per share. | 12 Jul 2024 | 5,000 | 25,424 (0%) | 0% | 45.0 | 225,059 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 45.01 per share. | 12 Jul 2024 | 5,000 | 25,424 (0%) | 0% | 45.0 | 225,058 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 37.39 per share. | 17 Jun 2024 | 11,950 | 311,885 (0%) | 0% | 37.4 | 446,770 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.09 per share. | 03 Jun 2024 | 7,500 | 329,822 (0%) | 0% | 4.1 | 30,675 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jun 2024 | 7,500 | 316,229 | - | - | Stock Option (Right to Buy) | |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.99 per share. | 03 Jun 2024 | 5,699 | 323,223 (0%) | 0% | 40.0 | 227,880 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 40.93 per share. | 03 Jun 2024 | 901 | 322,322 (0%) | 0% | 40.9 | 36,881 | Common Stock |
| Revolution Medicines Inc | Mark A. Goldsmith | Director, See Remarks | Sale of securities on an exchange or to another person at price $ 39.09 per share. | 03 Jun 2024 | 900 | 328,922 (0%) | 0% | 39.1 | 35,182 | Common Stock |